TEM News & Events

Tempus AI and NYU Langone Health announced a multi-year strategic collaboration aimed at transforming cancer care through advanced molecular profiling and data-driven insights. The collaboration will support NYU Langone Health's Center for Molecular Oncology at the Laura and Isaac Perlmutter Cancer Center.

Northwestern Medicine and Tempus AI are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provide nearly every patient across cancer types, including patients with early-stage cancer diagnoses, access to genomic testing.

Tempus AI announced a record Total Contract Value, TCV, of more than $1.1 billion as of December 31, 2025. During 2025, Tempus signed data agreements with over 70 customers, spanning both large and mid-sized pharma as an increasing number of biopharma companies are incorporating Tempus' "unique, multimodal dataset into their drug discovery and development efforts," the company said.